Yong Jun, Wang Yingchun, Xing Shouli, Bi Yufang, Li Ning, Zhao Shanna
Department of Vascular Surgery, Τhe Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Department of Pharmacy, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Exp Ther Med. 2019 Jun;17(6):4554-4560. doi: 10.3892/etm.2019.7476. Epub 2019 Apr 10.
Clinical efficacy of trimetazidine and plasmin combined with alprostadil in the treatment of lower extremity arteriosclerosis obliterans was investigated. A retrospective analysis was performed on 132 patients with lower extremity arteriosclerosis obliterans treated in Yantai Yuhuangding Hospital from March 2015 to August 2017. Among them, 68 patients were treated with trimetazidine combined with alprostadil (group A), and 64 patients were treated with plasmin combined with alprostadil (group B). Patients were administered 2 courses of treatment and observed with regard to therapeutic effects, changes in blood flow perfusion indicators (vascular peak velocity and blood flow) of the superficial femoral artery, posterior tibial artery and dorsalis pedis artery, in endothelial function, in left ankle brachial index, in pain-free walking distance and in maximum walking distance. After treatment, the vascular peak velocity of group B patients was lower than that in group A (P<0.05), but the blood flow was higher than that in group A (P<0.05). After treatment, endothelial esterase, high-sensitivity C-reactive protein and circulating endothelial cell count levels after treatment were lower than those before treatment (P<0.05), but nitric oxide level was higher than that before treatment (P<0.05). After treatment, the left ankle brachial index was lower in group A of patients than that in group B (P<0.05). After treatment, the maximum walking distance was significantly higher in group A patients than that in group B (P<0.05). After treatment, the pain-free walking distance and maximum walking distance of the two groups of patients were higher than those before treatment (P<0.05). Both trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans. The former is better than the latter in improving exercise capacity, but the latter is better than the former in improving blood flow perfusion in patients.
探讨曲美他嗪与纤溶酶联合前列地尔治疗下肢动脉硬化闭塞症的临床疗效。对2015年3月至2017年8月在烟台毓璜顶医院治疗的132例下肢动脉硬化闭塞症患者进行回顾性分析。其中，68例患者接受曲美他嗪联合前列地尔治疗（A组），64例患者接受纤溶酶联合前列地尔治疗（B组）。患者接受2个疗程的治疗，并观察治疗效果、股浅动脉、胫后动脉和足背动脉的血流灌注指标（血管峰值流速和血流量）变化、内皮功能、左踝肱指数、无痛步行距离和最大步行距离。治疗后，B组患者的血管峰值流速低于A组（P<0.05），但血流量高于A组（P<0.05）。治疗后，内皮酯酶、高敏C反应蛋白和循环内皮细胞计数水平低于治疗前（P<0.05），但一氧化氮水平高于治疗前（P<0.05）。治疗后，A组患者的左踝肱指数低于B组（P<0.05）。治疗后，A组患者的最大步行距离显著高于B组（P<0.05）。治疗后，两组患者的无痛步行距离和最大步行距离均高于治疗前（P<0.05）。曲美他嗪和纤溶酶联合前列地尔均能有效治疗下肢动脉硬化闭塞症。前者在改善运动能力方面优于后者，但后者在改善患者血流灌注方面优于前者。
